Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
Authors:
- Gili JosephGJGili Joseph
- Elisheva KleinEKElisheva Klein
- Yaniv LustigYLYaniv Lustig
- Yael Weiss-OttolenghiYWYael Weiss-Ottolenghi
- Keren AsrafKAKeren Asraf
- Victoria IndenbaumVIVictoria Indenbaum
- Sharon AmitSASharon Amit
- Or KrigerOKOr Kriger
- Mayan GilboaMGMayan Gilboa
- Yuval LevyYLYuval Levy
- Itai M. PessachIPItai M. Pessach
Open Access
Abstract
There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days after vaccination for immunogenicity, adverse events, and breakthrough infections. Ninety days after the first vaccine dose, the GeoMean (CI 95%) of IgG ascended to 1291.0 BAU (929.6–1790.2) for uninfected children and 1670.0 BAU (1131.0–2466.0) for Infected children. One hundred and eighty days after receiving the first dose of the vaccine, the titers decreased to 535.5 BAU (288.4–993.6) for the uninfected children, while only a small decline was detected among infected children—1479.0 (878.2–2490.0). The neutralizing antibodies titer almost did not change over time in the uninfected children, and even elevated for the infected children. Of the 110 vaccinated children, 75.5% were infected, with only mild COVID-19 infection symptoms. Child vaccination was found to be safe, with mild, mostly local, and of short duration, reported AEs. No serious adverse events (SAEs) were reported after vaccination. The durability of two doses of vaccine in children is longer, thus a booster may not be needed as early as in adults.Keywords
This publication has 52 references indexed in Scilit:
- COVID-19 in children: Pathogenesis and current statusAllergy and Asthma Proceedings, 2021
- COVID-19 Disease Severity Risk Factors for Pediatric Patients in ItalyPediatrics, 2020
- COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort studyThe Lancet Child & Adolescent Health, 2020
- Presenting symptoms of COVID-19 in children: a meta-analysis of published studiesBritish Journal of Anaesthesia, 2020
- Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort studyBMJ, 2020
- Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort studyThe Lancet Infectious Diseases, 2020
- SARS-COV-2 infection in children and newborns: a systematic reviewEuropean Journal of Pediatrics, 2020
- The Role of Children in the Dynamics of Intra Family Coronavirus 2019 Spread in Densely Populated AreaThe Pediatric Infectious Disease Journal, 2020
- Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adultsActa Paediatrica, 2020